<DOC>
	<DOCNO>NCT01635647</DOCNO>
	<brief_summary>Prime boost vaccination ChAd63 ME-TRAP follow eight week later MVA ME-TRAP show efficacy malaria infection test UK volunteer use sporozoite challenge experiment . It lead candidate vaccination strategy malaria . In field , Phase I study conduct adult Kenya The Gambia child infants The Gambia . The vaccination strategy appear safe well tolerated population , also show impressive immunogenicity , significantly different see UK trial efficacy show . In particular , recent data The Gambia show excellent safety immunogenicity infant malaria endemic area , would one benefit vaccine malaria . With clinical development background , investigator propose evaluate efficacy natural malaria infection important target group effective malaria vaccine , , 5-17 month infant child live malaria endemic area . The propose study area , Banfora , Burkina Faso , highly endemic Plasmodium falciparum malaria .</brief_summary>
	<brief_title>A Phase 1/2b Study Investigational Malaria Vaccination Strategy 5-17 Month Old Infants Children Burkina Faso</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy infant/child age 517 month time first study vaccination 2 . Informed consent parent/guardian 3 . Infant / child parent/guardian resident study area village anticipate available vaccination followup Clinically significant skin disorder ( psoriasis , contact dermatitis etc . ) , immunodeficiency , cardiovascular disease , respiratory disease , endocrine disorder , liver disease , renal disease , gastrointestinal disease , neurological illness . Weightforage Z score less 3 clinical sign malnutrition History allergic reaction , significant IgEmediated event , anaphylaxis immunisation History allergic disease reaction likely exacerbate component vaccine , e.g . egg product , Kathon , neomycin , betapropiolactone . Haemoglobin le 8.0 g/dL , judge clinically significant opinion investigator Serum Creatinine concentration great 70 Âµmol/L , judge clinically significant opinion investigator Serum ALT concentration great 45 U/L , judge clinically significant opinion investigator Blood transfusion within one month enrolment Previous vaccination experimental malaria vaccine . Administration vaccine immunoglobulin le one week vaccination study vaccine . Current participation another clinical trial , within 12 week study . Any finding opinion investigator would increase risk adverse outcome participation trial result incomplete poor quality data Known maternal HIV infection ( No test do study team ) Immunosuppressive therapy ( steroid , immune modulators immune suppressor ) within 3 month prior recruitment . ( For corticosteroid , mean prednisone , equivalent , great equal 0.5 mg/kg/day . Inhaled topical steroid allow . )</criteria>
	<gender>All</gender>
	<minimum_age>5 Months</minimum_age>
	<maximum_age>17 Months</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>